poisar

Stock

Sarepta Therapeutics, Inc. Common Stock (DE) SRPT

$22.14+13.71%

Overview

SRPT market data

Price History

SRPT price chart · 1M
O
19.21
H
22.58
L
18.77
C
22.14
Vol
417,473.00
Source
US equities market feed
Observed
Aug 27, 2026, 12:00 AM
Cadence
Five-minute page cache; daily and stored hourly bars
Status
fresh

Key Stats & Performance

Open
$19.21
Previous Close
$19.47
Day High
$22.58
Day Low
$18.77
52 Week High
$23.48
52 Week Low
$14.70
7 Day Return
+15.13%
30 Day Return
+43.30%
90 Day Return
+23.76%
1 Year Return
+7.03%
Daily Notional Volume
$9.2M
Latest daily bar volume multiplied by its closing price.

Valuation & Profitability

Provider-backed
P/E (TTM)
Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
Forward P/E
P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
EPS (TTM)
-$7.13
Diluted earnings per share over the trailing twelve months.
Beta
0.34
Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
Dividend Yield
Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
Profit Margin
-6.9%
Net income divided by revenue. Comparable within a sector, less so across sectors.
52w range
$14.68 – $25.32
Lowest and highest closing prices over the past 52 weeks.
Analyst Target
Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.

Display-only. Refreshed once per symbol per 24 hours · market cap $1.9B · P/B 1.98 · P/S 0.98.

Company News

8 captured
Sarepta Therapeutics Q2 Adj. EPS $0.64 Beats $0.26 Estimate, Sales $401.300M Beat $364.343M EstimateBenzinga · Aug 5, 2026, 8:14 PM
8-K filing — Sarepta Therapeutics, Inc. (SRPT)SEC EDGAR · Jul 27, 2026, 1:08 PM
Sarepta Therapeutics Appoints Michael Severino CEO, Effective July 28, Succeeding Doug IngramBenzinga · Jul 27, 2026, 12:37 PM
Piper Sandler Maintains Neutral on Sarepta Therapeutics, Lowers Price Target to $20Benzinga · Jul 9, 2026, 3:40 PM
Wolfe Research Upgrades Sarepta Therapeutics to Outperform, Announces $27 Price TargetBenzinga · Jul 9, 2026, 12:15 PM
Sarepta Moves Closer To FDA Approval For Duchenne Muscular Dystrophy DrugsBenzinga · Jun 30, 2026, 4:50 PM
Sarepta Therapeutics Says FDA Accept sNDAs For AMONDYS 45 And VYONDYS 53 For Treatment Of Duchenne Muscular Dystrophy; PDUFA Target Action Data February 28, 2027Benzinga · Jun 30, 2026, 12:40 PM
Small Caps Near Record Highs, Robinhood Rallies 12%: Stock Market TodayBenzinga · Jun 17, 2026, 5:40 PM

Decision & Score

Members

Our Tradable / Watch / Avoid decision and 0–100 conviction score for this symbol are members-only.

Create account to unlock

Trend & Pattern Evidence

Members

Trend alignment and backtested chart-pattern probabilities are members-only.

Create account to unlock

Sector Peer Ranking

Members

Ranked sector peers with scores and decisions are members-only.

Create account to unlock
Sarepta Therapeutics, Inc. Common Stock (DE) (SRPT) stock — price, valuation & news | Poisar